Radiation therapy for cholangiocarcinoma shifts toward neoadjuvant setting
- Radiation therapy for cholangiocarcinoma is undergoing a clinical shift toward the neoadjuvant setting, according to Ethan B.
- Most historical data for radiotherapy in cholangiocarcinoma comes from the adjuvant setting, notably the SWOG S0809 trial, which utilized radiation as a postoperative cleanup crew for margin-positive resections...
- Treatment strategies vary significantly depending on whether tumors are classified as intrahepatic or extrahepatic.
Radiation therapy for cholangiocarcinoma is undergoing a clinical shift toward the neoadjuvant setting, according to Ethan B. Ludmir, associate professor in the Department of Gastrointestinal Radiation Oncology at The University of Texas MD Anderson Cancer Center. Speaking ahead of the 2026 Chicago Cholangiocarcinoma Symposium, Ludmir outlined how modern radiation techniques are reshaping preoperative and nonoperative care for rare bile duct cancers.
Clinical Rationale for Neoadjuvant Radiation
Most historical data for radiotherapy in cholangiocarcinoma comes from the adjuvant setting, notably the SWOG S0809 trial, which utilized radiation as a postoperative cleanup crew for margin-positive resections and adverse pathologic features. However, Ludmir explained that clinicians now look to pancreatic cancer as a functional sister disease, particularly for distal extrahepatic cholangiocarcinoma located near the head of the pancreas. Patients generally tolerate neoadjuvant radiation better than postoperative treatment, and data from the pancreas space suggest preoperative radiation aids in achieving R0 resections by clearing disease margins prior to surgery. Surgical considerations remain central to this approach. According to Ludmir, some surgeons in the pancreas space observe that neoadjuvant radiation delivered six to eight weeks before surgery helps create edematous tissue planes that facilitate separating disease from major vasculature. Practice patterns and individual expertise continue to introduce clinical heterogeneity into how these fields are managed.
Patient Subsets and Tumor Location Differences
Treatment strategies vary significantly depending on whether tumors are classified as intrahepatic or extrahepatic. For intrahepatic cholangiocarcinoma, strong data supporting neoadjuvant or adjuvant radiation remain sparse, relying primarily on weak evidence from population studies and National Cancer Database analyses. While routine use is not standard, tertiary or quaternary care centers may employ targeted radiation in highly select intrahepatic cases to shrink tumors away from large liver vessels and secure an R0 resection during a hepatectomy. Distal extrahepatic cholangiocarcinoma represents the subset where neoadjuvant radiation shines brightest, given its anatomical proximity to pancreatic cancer models. Conversely, hilar tumors present an intermediate challenge categorized as extrahepatic disease without definitive consensus on optimal radiation sequencing.
Modern Techniques and Systemic Sequencing
Contemporary radiation management incorporates advanced modalities such as hypofractionation, stereotactic body radiation therapy, and proton beam therapy into preoperative and nonoperative care frameworks. These technologies are increasingly evaluated alongside systemic therapies, including chemoimmunotherapy regimens combining gemcitabine, cisplatin, and durvalumab. Clinical investigation into these sequencing strategies continues through active trials, including the ongoing randomized phase 2 HYPERION CCA trial registered under NCT06858735. These studies aim to clarify overall survival end points as targeted options expand, following the September 23, 2026, Food and Drug Administration approval of lirafugratinib for patients with FGFR2-altered cholangiocarcinoma.